Williams VSL, Carson RT, Nelson LM, MacDougall J, Fehnel SE, Lewis B, Johnston JM. Application of exploratory factor analysis to support the conceptual framework of PRO measures: results from a phase 2 study of irritable bowel syndrome with constipation. Poster presented at the International Society for Quality of Life Research (ISOQOL) 2010 Annual Meeting; November 18, 2010.
Fehnel S, Ervin CM, Lewis B, Carson RT, Johnston JM. Identifying endpoints for irritable bowel syndrome (IBS) clinical trials: incorporating the patient's voice. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. [abstract] Value Health. 2010 Nov; 13(7):A372.
Mangel AW, Williams VSL. Asimadoline in the treatment of irritable bowel syndrome. Expert Opin Investig Drugs. 2010 Oct 1;19(10):1257-64.
Yen L, Davis K, Longstreth G, Streck P, Hodgkins P. Resource utilization and health care costs associated with diverticulitis: results from a retrospective claims database analysis. Am J Gastroenterol. 2010 Oct 1;105(Suppl. 1):S431.
Nicandro JP, Tennis P, Bennett L, Hollis K, Shin P, Chuang E, Andrews E. Disability or restriction of daily activities is the most common indicator of disease severity in female patients with severe IBS-D: an analysis of the alosetron patient survey. Poster presented at the 2010 American College of Gastroenterology (ACG) Annual Scientific Meeting; October 2010. San Antonio, TX. [abstract] Am J Gastroenterol. 2010 Oct; 105(Suppl. 1):S410.
Johannes CB, Varas-Lorenzo C, McQuay L, Midkiff KD, Fife D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010 Sep 1;19(9):881-8.
Hollis KA, Tennis P, Nicandro J, Chuang E, Sweeney CT, Bennett L, Andrews E. Temporal trends in compliance with the alosetron risk management program. Poster presented at the 26th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2010. Brighton, United Kingdom.
Hollis KA, Calingaert B, Price M, Andrews E, Moy L, Kooijmans M, Cristiano L, Bozic C. Tysabri TOUCH prescriber program risk management program (RiskMAP) surveys. Poster presented at the 26th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2010. Brighton, United Kingdom.
Riera Guardia N, Castellsague J, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A, Nicotra F. The SOS Project: nonsteroidal anti-inflammatory drugs and upper gastrointestinal complications: meta-analysis of epidemiological studies. Poster presented at the 26th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2010. Brighton, UK. [abstract] Pharmacoepidemiol Drug Saf. 2010 Aug 24; 19(Suppl 1):S314.
Arana A, Allen S, Burkowitz J, Fantoni V, Ghatnekar O, Rico MT, Vanhaverbeke N, Wentworth CE, Brosa M, Arellano FM. Infliximab paediatric Crohn's disease educational plan: a European, cross-sectional, multicentre evaluation. Drug Saf. 2010 Jun;33(6):489-501.
Fehnel SE, Ervin CM, Shiff SJ, Johnston JM, Kurtz CB, Carson RT. Assessing treatment response in chronic constipation clinical trials: concepts elicited through qualitative interviews with patients. Poster presented at the 2010 Digestive Disease Week; May 1, 2010.
Earnshaw S, Pignone M, Fendrick AM, Scheiman J, McDade C. Cost-effectiveness of proton pump inhibitors for prevention of gastrointestinal adverse events when using aspirin for primary cardiovascular prevention. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A166.
Ervin CM, Fehnel S, Carson R, Kurtz C, Shiff S, Johnston J. Selecting chronic constipation (CC) clinical trial endpoints: incorporating the patient's voice. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 28, 2010. [abstract] Value Health. 2010 May; 13(3):A74.
Nicandro J, Tennis P, Shin P, Hickman P, Bennett L, Hollis KA, Andrews E. One-year treatment continuation with alosetron is high irrespective of ibs-d severity criteria. Poster presented at the 2010 Digestive Disease Week; April 30, 2010.
Earnshaw SR, Klok RM, Iyer S, McDade C. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness--a cost-effectiveness analysis. Aliment Pharmacol Ther. 2010 Apr 1;31(8):911-21.
Iyer S, Davis KL, Candrilli S. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag Care. 2010 Mar 1;19(3):44-51.
Koch GG, Amara LA, Forster JK, McSorley DJ, Peace KE. Statistical issues in the design and analysis of ulcer healing and recurrence studies. Drug Inf J. 1993 Jul;27(3):805-24.
Johnson JA, Euler AR, Northcutt AR, McSorley DJ. Ranitidine 300mg at bedtime is effective for gastric ulcers: a 12-week, multicenter, randomized, double-blind, placebo-controlled comparison. Am J Gastroenterol. 1993;88(7):1071-5.
Marshall B, Ciociola AA, McSorley DJ, Webb DD. Computerized phone-in symptom recording system correlates with patient recorded symptom diary card for patients with non-ulcer dyspepsia. Am J Gastroenterol. 1993;91(9):1992.